Cargando…
Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity
The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransfera...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530474/ https://www.ncbi.nlm.nih.gov/pubmed/26194781 http://dx.doi.org/10.1038/ncomms8719 |
_version_ | 1782384906286923776 |
---|---|
author | Zuegg, Johannes Muldoon, Craig Adamson, George McKeveney, Declan Le Thanh, Giang Premraj, Rajaratnam Becker, Bernd Cheng, Mu Elliott, Alysha G. Huang, Johnny X. Butler, Mark S. Bajaj, Megha Seifert, Joachim Singh, Latika Galley, Nicola F. Roper, David I. Lloyd, Adrian J. Dowson, Christopher G. Cheng, Ting-Jen Cheng, Wei-Chieh Demon, Dieter Meyer, Evelyne Meutermans, Wim Cooper, Matthew A. |
author_facet | Zuegg, Johannes Muldoon, Craig Adamson, George McKeveney, Declan Le Thanh, Giang Premraj, Rajaratnam Becker, Bernd Cheng, Mu Elliott, Alysha G. Huang, Johnny X. Butler, Mark S. Bajaj, Megha Seifert, Joachim Singh, Latika Galley, Nicola F. Roper, David I. Lloyd, Adrian J. Dowson, Christopher G. Cheng, Ting-Jen Cheng, Wei-Chieh Demon, Dieter Meyer, Evelyne Meutermans, Wim Cooper, Matthew A. |
author_sort | Zuegg, Johannes |
collection | PubMed |
description | The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransferases, which are essential for peptidoglycan polymerization, while displaying a low rate of resistance. Unfortunately, the lipophilicity of moenomycin leads to unfavourable pharmacokinetic properties that render it unsuitable for systemic administration. In this study, we show that using moenomycin and other glycosyltransferase inhibitors as templates, we were able to synthesize compound libraries based on novel pyranose scaffold chemistry, with moenomycin-like activity, but with improved drug-like properties. The novel compounds exhibit in vitro inhibition comparable to moenomycin, with low toxicity and good efficacy in several in vivo models of infection. This approach based on non-planar carbohydrate scaffolds provides a new opportunity to develop new antibiotics with low propensity for resistance induction. |
format | Online Article Text |
id | pubmed-4530474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Pub. Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45304742015-08-11 Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity Zuegg, Johannes Muldoon, Craig Adamson, George McKeveney, Declan Le Thanh, Giang Premraj, Rajaratnam Becker, Bernd Cheng, Mu Elliott, Alysha G. Huang, Johnny X. Butler, Mark S. Bajaj, Megha Seifert, Joachim Singh, Latika Galley, Nicola F. Roper, David I. Lloyd, Adrian J. Dowson, Christopher G. Cheng, Ting-Jen Cheng, Wei-Chieh Demon, Dieter Meyer, Evelyne Meutermans, Wim Cooper, Matthew A. Nat Commun Article The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransferases, which are essential for peptidoglycan polymerization, while displaying a low rate of resistance. Unfortunately, the lipophilicity of moenomycin leads to unfavourable pharmacokinetic properties that render it unsuitable for systemic administration. In this study, we show that using moenomycin and other glycosyltransferase inhibitors as templates, we were able to synthesize compound libraries based on novel pyranose scaffold chemistry, with moenomycin-like activity, but with improved drug-like properties. The novel compounds exhibit in vitro inhibition comparable to moenomycin, with low toxicity and good efficacy in several in vivo models of infection. This approach based on non-planar carbohydrate scaffolds provides a new opportunity to develop new antibiotics with low propensity for resistance induction. Nature Pub. Group 2015-07-21 /pmc/articles/PMC4530474/ /pubmed/26194781 http://dx.doi.org/10.1038/ncomms8719 Text en Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Zuegg, Johannes Muldoon, Craig Adamson, George McKeveney, Declan Le Thanh, Giang Premraj, Rajaratnam Becker, Bernd Cheng, Mu Elliott, Alysha G. Huang, Johnny X. Butler, Mark S. Bajaj, Megha Seifert, Joachim Singh, Latika Galley, Nicola F. Roper, David I. Lloyd, Adrian J. Dowson, Christopher G. Cheng, Ting-Jen Cheng, Wei-Chieh Demon, Dieter Meyer, Evelyne Meutermans, Wim Cooper, Matthew A. Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
title | Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
title_full | Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
title_fullStr | Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
title_full_unstemmed | Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
title_short | Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
title_sort | carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530474/ https://www.ncbi.nlm.nih.gov/pubmed/26194781 http://dx.doi.org/10.1038/ncomms8719 |
work_keys_str_mv | AT zueggjohannes carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT muldooncraig carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT adamsongeorge carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT mckeveneydeclan carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT lethanhgiang carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT premrajrajaratnam carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT beckerbernd carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT chengmu carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT elliottalyshag carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT huangjohnnyx carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT butlermarks carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT bajajmegha carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT seifertjoachim carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT singhlatika carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT galleynicolaf carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT roperdavidi carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT lloydadrianj carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT dowsonchristopherg carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT chengtingjen carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT chengweichieh carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT demondieter carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT meyerevelyne carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT meutermanswim carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity AT coopermatthewa carbohydratescaffoldsasglycosyltransferaseinhibitorswithinvivoantibacterialactivity |